Plain-English translation of NCT07734194 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a new sedation approach for people undergoing a procedure called pulsed-field ablation to treat irregular heartbeats (atrial fibrillation). Instead of putting you into deep sleep or general anesthesia, doctors will use remimazolam paired with fentanyl to keep you lightly sedated and comfortable during the procedure. The study wants to see whether this lighter sedation approach works well and is safe for this type of heart treatment.
Currently, doctors typically use deeper sedation or full anesthesia for this heart procedure, which carries more risks and requires more recovery time. This medication combination offers a potential middle ground—keeping patients comfortable while awake enough to respond, which might reduce complications and help people recover faster.
You likely qualify if…
You likely don't qualify if…
You will receive the pulsed-field ablation procedure at a medical center while under the lighter sedation provided by the study medications. Before the procedure starts, you'll receive doses of both medications through an IV line, and additional doses may be given as needed during the procedure. Throughout the procedure, medical staff will carefully monitor your vital signs, oxygen levels, and comfort, and afterward you'll be asked about your experience and how you felt during the treatment.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
Czechia
Sponsor
Charles University, Czech Republic
Enrollment target
~20 participants
Started
January 2026
Primary completion
August 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Marek Hozman, MD, PhD
Charles University, Czech Republic
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.